Pyxis Oncology, Inc. (PYXS) has a negative trailing P/E of -1.2, meaning the company is currently unprofitable on a trailing twelve-month (TTM) basis. Trailing earnings yield is -83.20%.
Criteria proven by this page:
Overall SharesGrow Score: 53/100 with 3/7 criteria passed.
| Year | P/E (TTM) | PEG Ratio | P/B Ratio | P/S Ratio | Dividend Yield |
|---|---|---|---|---|---|
| 2019 | -163.4 | 0.00 | -157.58 | 0.00 | - |
| 2020 | -35.3 | -0.09 | -28.95 | 0.00 | - |
| 2021 | -4.7 | -0.01 | 1.35 | 0.00 | - |
| 2022 | -0.4 | -0.01 | 0.28 | 0.00 | - |
| 2023 | -1.0 | 0.02 | 0.57 | 0.00 | - |
| 2024 | -1.2 | 0.04 | 0.76 | 5.65 | - |
| 2025 | -0.9 | 0.30 | 1.34 | 5.16 | - |
| Year | EPS (Diluted) | Revenue | Net Income | Net Margin |
|---|---|---|---|---|
| 2019 | $-0.08 | $0.00 | $-2.67M | - |
| 2020 | $-0.37 | $0.00 | $-12.76M | - |
| 2021 | $-2.53 | $0.00 | $-81.54M | - |
| 2022 | $-3.57 | $0.00 | $-117.95M | - |
| 2023 | $-1.85 | $0.00 | $-73.79M | - |
| 2024 | $-1.32 | $16.15M | $-77.33M | -478.9% |
| 2025 | $-1.28 | $13.86M | $-79.62M | -574.5% |
| Year | EPS (Avg) | EPS Range | Revenue (Avg) | Revenue Range | Analysts |
|---|---|---|---|---|---|
| 2026 | $-1.30 | $-1.48 – $-0.99 | $50K | $50K – $50K | 6 |
| 2027 | $-1.32 | $-1.78 – $-0.97 | $5M | $5M – $5M | 6 |
| 2028 | $-1.34 | $-1.99 – $-0.40 | $15.79M | $15.79M – $15.79M | 6 |
| 2029 | $-1.02 | $-1.02 – $-1.02 | $53.85M | $53.85M – $53.85M | 4 |
| 2030 | $-0.63 | $-0.63 – $-0.63 | $125.16M | $125.16M – $125.16M | 2 |
